

Neurological Immune-Related Adverse Event Management Algorithm (1)

Grading of neurological symptoms	Action	Follow up
<p>Grade 1^a</p> <p>For example:</p> <ul style="list-style-type: none"> - Reduced motor or sensory function in limbs (e.g. peripheral neuropathy) - Muscle or neuropathic pain (no or minimal effect on ADLs) 	<p>Investigations</p> <ul style="list-style-type: none"> • Urgent neurology referral • Measure creatine kinase • Swallow and respiratory assessment <p>Management</p> <ul style="list-style-type: none"> • Hold I-O therapy until grade confirmed (continue I-O therapy only if confirmed G1) • Close monitoring of symptoms 	<p>If worsens:</p> <ul style="list-style-type: none"> • Treat as G2 or above
<p>Grade 2</p> <p>For example:</p> <ul style="list-style-type: none"> - Features of peripheral neuropathy which have some effect on ADLs or otherwise causes symptoms concerning to the patient such as pain - Features of myasthenia or myopathy with ocular symptoms or mild generalised weakness only - Autonomic neuropathy which has some effect on ADLs 	<p>Investigations</p> <ul style="list-style-type: none"> • Urgent neurology referral • Measure creatine kinase • Swallow and respiratory assessment <p>Management</p> <ul style="list-style-type: none"> • Delay I-O therapy^b • Commence oral prednisolone (0.5 - 1mg/kg, max 60mg OD) with PPI cover • If symptoms improve, wean steroids as per regime below (wean over at least 1 month)^c 	<p>If no improvement:</p> <ul style="list-style-type: none"> • Commence methylprednisolone 1-2mg/kg/day IV or oral • Rediscuss with neurology
<p>Grade 3 – 4</p> <p>Severe or life-threatening symptoms</p> <p>For example:</p> <ul style="list-style-type: none"> - Guillain-Barre type syndrome - Myasthenia gravis or myositis with any dysphagia, facial weakness, respiratory muscle weakness or rapidly progressive symptoms - Transverse myelitis - Brainstem or brain syndromes 	<p>Investigations</p> <ul style="list-style-type: none"> • As per G1/2 • Admit to hospital • Autoantibody tests <p>Consider the following as appropriate:</p> <ul style="list-style-type: none"> • MRI head and spinal cord • NCS and EMG • MRI muscles <p>Management</p> <ul style="list-style-type: none"> • See specific algorithms overleaf • Discontinue I-O therapy • Commence methylprednisolone 1-2mg/kg/day IV or oral • Daily neurological assessment 	<p>If no improvement:</p> <ul style="list-style-type: none"> • Consider IVIg or plasmapheresis following consultation with neurology^d • For life-threatening symptoms, consider methylprednisolone 1g IV for 3-5 days

^aNote that suspected Myasthenia Gravis or Guillain-Barre like syndromes cannot be Grade 1. Please see specific algorithm overleaf.

^bOnly consider re-challenge with I-O therapy if:

1. Patient had confirmed G1 - 2 symptoms
2. Symptoms improved or stabilised on low dose or no steroids
3. Patient had a convincing response to I-O therapy prior to the development of G1 - 2 symptoms

^cConsider bone protection (with AdCalD3 +/- bisphosphonates), BM monitoring and PCP prophylaxis in patients with prolonged high dose steroids.

^dConsider IVIg (2g/kg cumulative dose split over 3-5 days) or plasmapheresis (PLEX, 5-7 sessions) if rapidly progressing symptoms

Neurological Immune-Related Adverse Event Management Algorithm (2)

Suspected neurological syndrome	Investigations	Management
<p>Myasthenia Gravis or myositis</p> <p><i>Suspect in patients with symptoms such as new proximal muscle weakness, ptosis, diplopia, dysphagia, slurred speech, neck or facial muscle weakness, respiratory muscle weakness (sometimes muscle pain in myositis)</i></p>	<ul style="list-style-type: none"> • Urgent neurology advice • Swallow and respiratory assessment (FVC) • Measure AChR and MuSK antibodies, creatine kinase, myositis antibody screen • Consider MRI head +/- cervical spine to exclude alternative diagnoses • Consider troponin + ECG to exclude concurrent myositis • Consider nerve conduction studies/ EMG following consultation with neurology 	<ul style="list-style-type: none"> • Hold I-O therapy • Admission to hospital as patients can deteriorate rapidly • Commence pyridostigmine 30mg PO TDS following neurology review (can gradually increase to up to 120mg PO QDS max based on symptoms, response and tolerance) • Commence oral prednisolone 0.5mg/kg/day. Wean based on neurology advice. • If severe symptoms- IVIG or plasmapheresis with likely ITU admission.
<p>Guillain-Barre Syndrome</p> <p><i>Suspect in patients with (usually ascending) symptoms such as new bilateral weakness, sensory changes, areflexia, dysphagia, respiratory muscle weakness, autonomic dysfunction</i></p>	<ul style="list-style-type: none"> • Urgent neurology advice • Swallow and respiratory assessment (FVC) • Consider MRI whole spine to exclude compressive lesion • Consider lumbar puncture (inc. cell count and differential, protein, glucose, bacterial MCS +/- virology & cytology) • Consider paraneoplastic workup, serum antiganglioside • Consider nerve conduction studies following consultation with neurology 	<ul style="list-style-type: none"> • Hold I-O therapy • Regularly reassess neurology • Admit to hospital capable of rapid transfer to ITU setting • Commence IVIg (2g/kg ideal weight dose split over 5 days) • Whilst steroids are not usually recommended for idiopathic GBS, trial of steroids can be considered for suspected immunotherapy induced GBS e.g. 2-4mg/kg/day IV methylprednisolone or 1g for G3/4 with IVIG or PLEX
<p>Demyelinating diseases including multiple sclerosis, transverse myelitis</p> <p><i>Suspect if symptoms such as new weakness, sensory changes, impaired coordination, brainstem syndromes (oculomotor changes or facial/ trigeminal deficits), acute loss of vision.</i></p>	<ul style="list-style-type: none"> • Urgent neurology advice • MRI brain / spine with contrast • Consider lumbar puncture (inc. oligoclonal bands, autoimmune panel) • Consider B12, copper, HIV, syphilis, CMV, ANA, TSH, AQP-4 IgG, MOG-IgG, neuronal antibodies (for paraneoplastic syndromes) 	<ul style="list-style-type: none"> • Hold I-O therapy • Commence methylprednisolone 2mg/kg (or consider 1g/ day) • Consider IVIg or PLEX if no improvement or worsening of symptoms after 3 days following consultation with neurology
<p>Aseptic meningitis / encephalitis</p> <p><i>Aseptic meningitis - suspect in patients with fever, headache, neck stiffness, nausea</i></p> <p><i>Encephalitis - suspect in patients with fever, headache, new confusion, seizures, drowsiness, focal neurological deficits</i></p>	<ul style="list-style-type: none"> • Urgent neurology advice • MRI head with contrast • Consider lumbar puncture (inc. opening pressure, cell count and differential, protein, glucose, bacterial MCS +/- virology and cytology) • Consider autoimmune and paraneoplastic panels • Consider 9am cortisol and ACTH to exclude adrenal insufficiency 	<ul style="list-style-type: none"> • Hold I-O therapy • Empiric antibiotic and antiviral therapy pending PCR results • Commence oral prednisolone 0.5-1mg/kg/day (max 60mg OD) or IV methylprednisolone 1-2mg/kg/day. Exclude bacterial and viral infections before starting high dose steroids • For refractory encephalitis, consider methylprednisolone 1g/day for 3 days +/- IVIg or PLEX following neurology discussion

Issue date:	
Version No:	2.0
Authors:	Danica Fernandes Anil Babar Alekhia Nippani Maria Leite